Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DWIGHT DENMAN BLAKE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1811938814
CMS profile
173473
Location
UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$473.01

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $473.01 5

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $207.52 2
Dexcom, Inc. $127.22 1
Lilly USA, LLC $122.25 1
Currax Pharmaceuticals LLC $16.02 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DWIGHT DENMAN BLAKE

NPI 1811938814 · CMS profile ID 173473

Allopathic & Osteopathic Physicians / Internal Medicine

UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811938814?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811938814?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811938814?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1811938814?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $473.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Currax Pharmaceuticals LLC $16.0211/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925766721 CMS
Lilly USA, LLC $122.2511/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917982529 CMS
Novo Nordisk Inc $103.6008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899414961 CMS
Dexcom, Inc. $127.2202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957341715 CMS
Novo Nordisk Inc $103.9202/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899414967 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,138.93 6
PY2020 $1,159.49 24
PY2021 $122.45 1
PY2022 $473.01 5
PY2024 $1,818.96 5
PY2025 $369.25 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,386,564.75 80
PY2024 Recipient $57,732.20 4
PY2024 Principal investigator $2,455,115.26 49
PY2023 Recipient $2,277.99 4
PY2023 Principal investigator $2,791,306.83 51
PY2022 Recipient $92,276.00 3
PY2022 Principal investigator $3,022,384.19 43
PY2021 Recipient $6,646.99 2
PY2021 Principal investigator $1,337,039.14 22
PY2020 Recipient $1,658.45 3
PY2020 Principal investigator $145,341.90 6
PY2019 Recipient $24,425.96 3
PY2019 Principal investigator $177,128.41 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $1,839.22 12/31/2021 Non-covered Recipient Entity
SKY JONES FAMILY DENTISTRY
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 789008605
Principal investigator 1 Eli Lilly and Company $238,620.00 11/16/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819466247
Principal investigator 1 Allergan, Inc. $1,844.90 10/13/2021 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 789008603
Recipient Eli Lilly and Company $6,597.33 09/09/2021 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819443807
Principal investigator 1 Eli Lilly and Company $41.02 08/20/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819464735
Principal investigator 1 Allergan, Inc. $8,500.00 07/01/2021 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 789008599
Principal investigator 1 Allergan, Inc. $2,500.00 07/01/2021 Non-covered Recipient Entity
BALANCED LIFE HEALTH CARE SOLUTIONS (DBA) SKY CL
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 789008601
Recipient Eli Lilly and Company $49.66 06/30/2021 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 819443877
Principal investigator 1 Eli Lilly and Company $401,939.00 06/07/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 819466843
Principal investigator 1 Eli Lilly and Company $415,200.00 06/01/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819466841
Principal investigator 1 Eli Lilly and Company $49.66 05/31/2021 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 819459543
Principal investigator 1 Eli Lilly and Company $8,630.05 05/18/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819467159
Principal investigator 1 Eli Lilly and Company $47.50 04/30/2021 Non-covered Recipient Entity
MILLENNIUM RESEARCH LLC
A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 819462655
Principal investigator 1 Eli Lilly and Company $49.66 04/30/2021 Non-covered Recipient Entity
SHARP MESA VISTA HOSPITAL
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 819466823
Principal investigator 1 Eli Lilly and Company $151,309.00 04/27/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819467153
Principal investigator 1 Eli Lilly and Company $1,250.00 04/26/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819466243
Principal investigator 1 Eli Lilly and Company $14,989.56 03/03/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 819464169
Principal investigator 1 Eli Lilly and Company $2,531.00 02/23/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819464167
Principal investigator 1 Eli Lilly and Company $10,379.24 02/02/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819468721
Principal investigator 1 Eli Lilly and Company $3,041.08 01/29/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 819464173
Principal investigator 1 Eli Lilly and Company $101.00 01/29/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819466837
Principal investigator 1 Eli Lilly and Company $102.25 01/29/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819467155
Principal investigator 1 Eli Lilly and Company $64,575.00 01/19/2021 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 819464519
Principal investigator 1 PFIZER INC. $9,500.00 01/09/2021 Non-covered Recipient Entity
SKY Clinical Research Network Group
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832615077